PVT1

Summary

PVT1 (Pvt1 oncogene, HGNC:9709) is a long non-coding RNA gene on chromosome 8q24.21.

This gene represents a long non-coding RNA locus that has been identified as a candidate oncogene. Increased copy number and overexpression of this gene are associated with many types of cancers including breast and ovarian cancers, acute myeloid leukemia and Hodgkin lymphoma. Allelic variants of this gene are also associated with end-stage renal disease attributed to type 1 diabetes. Consistent with its association with various types of cancer, transcription of this gene is regulated by the tumor suppressor p53 through a canonical p53-binding site, and it has been implicated in regulating levels of the proto-oncogene MYC to promote tumorigenesis.

Source: NCBI Gene 5820 — RefSeq curated summary.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9709
Approved symbol	PVT1
Name	Pvt1 oncogene
Location	8q24.21
Locus type	RNA, long non-coding
Status	Approved
Aliases	NCRNA00079, LINC00079, onco-lncRNA-100, MIR1204HG, TP53LC09
Ensembl gene	ENSG00000249859
Ensembl biotype	lncRNA
OMIM	165140
Entrez	5820
RNAcentral	URS00026A27F2 — lncRNA, 1952 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 426 — 426 lncRNA

ENST00000504719, ENST00000512617, ENST00000513868, ENST00000517525, ENST00000517790, ENST00000517838, ENST00000518528, ENST00000519481, ENST00000520913, ENST00000521122, ENST00000521600, ENST00000521951, ENST00000522414, ENST00000522875, ENST00000522963, ENST00000523068, ENST00000523190, ENST00000523328, ENST00000523427, ENST00000524165, ENST00000650846, ENST00000650930, ENST00000651568, ENST00000651587, ENST00000651664, ENST00000652492, ENST00000652695, ENST00000652728, ENST00000652816, ENST00000652883, ENST00000652993, ENST00000653406, ENST00000653497, ENST00000653522, ENST00000653608, ENST00000653845, ENST00000653853, ENST00000653990, ENST00000654091, ENST00000654105, ENST00000654324, ENST00000654369, ENST00000655099, ENST00000655148, ENST00000655594, ENST00000655783, ENST00000656077, ENST00000656168, ENST00000656396, ENST00000656402, ENST00000656411, ENST00000656491, ENST00000656532, ENST00000656693, ENST00000656880, ENST00000656948, ENST00000656999, ENST00000657112, ENST00000657183, ENST00000657211, ENST00000657289, ENST00000657297, ENST00000657356, ENST00000657384, ENST00000657449, ENST00000657451, ENST00000657517, ENST00000657596, ENST00000657667, ENST00000657682, ENST00000657693, ENST00000657844, ENST00000657945, ENST00000658018, ENST00000658065, ENST00000658158, ENST00000658242, ENST00000658305, ENST00000658350, ENST00000658429, ENST00000658556, ENST00000658840, ENST00000659106, ENST00000659326, ENST00000659625, ENST00000659666, ENST00000659892, ENST00000659912, ENST00000660069, ENST00000660122, ENST00000660146, ENST00000660200, ENST00000660438, ENST00000660456, ENST00000660631, ENST00000660659, ENST00000660781, ENST00000660896, ENST00000660912, ENST00000661160, ENST00000661205, ENST00000661391, ENST00000661625, ENST00000661830, ENST00000661988, ENST00000662061, ENST00000662410, ENST00000662413, ENST00000662709, ENST00000662766, ENST00000663059, ENST00000663461, ENST00000663715, ENST00000663753, ENST00000664139, ENST00000664214, ENST00000664265, ENST00000664293, ENST00000664299, ENST00000664610, ENST00000664742, ENST00000664924, ENST00000664995, ENST00000665166, ENST00000665175, ENST00000665246, ENST00000665372, ENST00000665698, ENST00000665721, ENST00000665737, ENST00000665856, ENST00000666039, ENST00000666076, ENST00000666080, ENST00000666105, ENST00000666147, ENST00000666223, ENST00000666353, ENST00000666452, ENST00000666776, ENST00000666777, ENST00000666842, ENST00000666878, ENST00000667149, ENST00000667204, ENST00000667305, ENST00000667418, ENST00000667539, ENST00000667630, ENST00000667714, ENST00000668098, ENST00000668123, ENST00000668215, ENST00000668351, ENST00000668479, ENST00000668480, ENST00000668619, ENST00000669082, ENST00000669132, ENST00000669272, ENST00000669407, ENST00000669416, ENST00000669509, ENST00000669951, ENST00000670009, ENST00000670204, ENST00000670223, ENST00000670532, ENST00000670535, ENST00000670602, ENST00000670626, ENST00000670714, ENST00000670795, ENST00000671088, ENST00000671092, ENST00000671587, ENST00000685606, ENST00000685634, ENST00000689722, ENST00000690350, ENST00000690788, ENST00000692433, ENST00000692980, ENST00000700930, ENST00000701558, ENST00000701700, ENST00000701841, ENST00000701958, ENST00000702405, ENST00000702532, ENST00000844540, ENST00000844541, ENST00000844542, ENST00000844543, ENST00000844544, ENST00000844545, ENST00000844546, ENST00000844547, ENST00000844548, ENST00000844549, ENST00000844550, ENST00000844551, ENST00000844552, ENST00000844553, ENST00000844554, ENST00000844555, ENST00000844556, ENST00000844557, ENST00000844558, ENST00000844559, ENST00000844560, ENST00000844561, ENST00000844562, ENST00000844563, ENST00000844564, ENST00000844565, ENST00000844566, ENST00000844567, ENST00000844568, ENST00000844569, ENST00000844570, ENST00000844571, ENST00000844572, ENST00000844573, ENST00000844574, ENST00000844575, ENST00000844576, ENST00000844577, ENST00000844578, ENST00000844579, ENST00000844580, ENST00000844581, ENST00000844582, ENST00000844583, ENST00000844584, ENST00000844585, ENST00000844586, ENST00000844587, ENST00000844588, ENST00000844589, ENST00000844590, ENST00000844591, ENST00000844592, ENST00000844593, ENST00000844594, ENST00000844595, ENST00000844596, ENST00000844597, ENST00000844598, ENST00000844599, ENST00000844600, ENST00000844601, ENST00000844602, ENST00000844603, ENST00000844604, ENST00000844605, ENST00000844606, ENST00000844607, ENST00000844608, ENST00000844609, ENST00000844610, ENST00000844611, ENST00000844612, ENST00000844613, ENST00000844614, ENST00000844615, ENST00000844616, ENST00000844617, ENST00000844618, ENST00000844619, ENST00000844620, ENST00000844621, ENST00000844622, ENST00000844623, ENST00000844624, ENST00000844625, ENST00000844626, ENST00000844627, ENST00000844628, ENST00000844629, ENST00000844630, ENST00000844631, ENST00000844632, ENST00000844633, ENST00000844634, ENST00000844635, ENST00000844636, ENST00000844637, ENST00000844638, ENST00000844639, ENST00000844640, ENST00000844641, ENST00000844642, ENST00000844643, ENST00000844645, ENST00000844646, ENST00000844647, ENST00000844648, ENST00000844649, ENST00000844651, ENST00000844653, ENST00000844655, ENST00000844656, ENST00000844657, ENST00000844659, ENST00000844660, ENST00000844662, ENST00000844663, ENST00000844664, ENST00000844665, ENST00000844666, ENST00000844667, ENST00000844668, ENST00000844669, ENST00000844670, ENST00000844671, ENST00000844672, ENST00000844673, ENST00000844674, ENST00000844675, ENST00000844676, ENST00000844677, ENST00000844678, ENST00000844679, ENST00000844680, ENST00000844681, ENST00000844691, ENST00000844694, ENST00000844695, ENST00000844697, ENST00000844700, ENST00000844702, ENST00000844704, ENST00000844727, ENST00000844728, ENST00000844729, ENST00000844730, ENST00000844731, ENST00000844732, ENST00000844733, ENST00000844734, ENST00000844735, ENST00000844736, ENST00000844737, ENST00000844738, ENST00000844739, ENST00000844740, ENST00000844741, ENST00000844742, ENST00000844743, ENST00000844744, ENST00000844745, ENST00000844746, ENST00000844747, ENST00000844748, ENST00000844749, ENST00000844750, ENST00000844751, ENST00000844752, ENST00000844753, ENST00000844754, ENST00000844755, ENST00000844756, ENST00000844757, ENST00000844758, ENST00000844759, ENST00000844760, ENST00000844761, ENST00000844762, ENST00000844763, ENST00000844764, ENST00000844765, ENST00000844766, ENST00000844767, ENST00000844768, ENST00000844769, ENST00000844770, ENST00000844771, ENST00000844772, ENST00000844773, ENST00000844774, ENST00000844775, ENST00000844776, ENST00000844777, ENST00000844778, ENST00000844779, ENST00000844780, ENST00000844781, ENST00000844782, ENST00000844783, ENST00000844784, ENST00000844785, ENST00000844786, ENST00000844787, ENST00000844788, ENST00000844789, ENST00000844790, ENST00000844791, ENST00000844792, ENST00000844793, ENST00000844794, ENST00000844795, ENST00000844796, ENST00000844797, ENST00000844798, ENST00000844799, ENST00000844800, ENST00000844801, ENST00000844802, ENST00000844803, ENST00000844804, ENST00000844805, ENST00000844806, ENST00000844807, ENST00000844808, ENST00000844809, ENST00000844810, ENST00000844811, ENST00000844812, ENST00000844813, ENST00000844814, ENST00000844815, ENST00000844816, ENST00000844817, ENST00000844818, ENST00000844819

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000504719 — 4 exons

Exon	Start	End
ENSE00002027891	127855155	127855319
ENSE00002031819	127890589	127890998
ENSE00004271496	127794527	127794734
ENSE00004271635	127932465	127932716

Expression profiles

Bgee: expression breadth ubiquitous, 227 present calls, max score 94.71.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 40.2704 / max 13543.8216, expressed in 1761 samples.

FANTOM5 promoters (37 alternative TSS)

Promoter ID	TPM avg	Samples expressed
90676	27.0285	1696
90682	2.9794	768
90726	1.6786	716
90748	1.5845	81
90751	0.8112	180
90722	0.7297	243
90681	0.4993	265
90747	0.4604	65
90723	0.4366	245
90732	0.4348	216

Top tissues by expression

283 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower esophagus mucosa	UBERON:0035834	94.71	gold quality
adrenal tissue	UBERON:0018303	94.23	gold quality
colonic epithelium	UBERON:0000397	93.45	gold quality
left ovary	UBERON:0002119	92.60	gold quality
right ovary	UBERON:0002118	92.43	gold quality
right adrenal gland	UBERON:0001233	91.23	gold quality
right adrenal gland cortex	UBERON:0035827	91.05	gold quality
left adrenal gland cortex	UBERON:0035825	90.71	gold quality
left adrenal gland	UBERON:0001234	90.40	gold quality
adrenal gland	UBERON:0002369	90.35	gold quality
adrenal cortex	UBERON:0001235	90.19	gold quality
ovary	UBERON:0000992	89.03	gold quality
tonsil	UBERON:0002372	88.68	gold quality
tendon of biceps brachii	UBERON:0008188	87.96	silver quality
esophagus mucosa	UBERON:0002469	87.41	gold quality
stromal cell of endometrium	CL:0002255	87.12	gold quality
lymph node	UBERON:0000029	86.82	gold quality
granulocyte	CL:0000094	86.23	gold quality
spleen	UBERON:0002106	86.19	gold quality
right uterine tube	UBERON:0001302	85.56	gold quality
left uterine tube	UBERON:0001303	85.13	gold quality
monocyte	CL:0000576	84.79	gold quality
leukocyte	CL:0000738	84.75	gold quality
mononuclear cell	CL:0000842	84.61	gold quality
ectocervix	UBERON:0012249	84.40	gold quality
vagina	UBERON:0000996	84.23	gold quality
sural nerve	UBERON:0015488	83.89	gold quality
blood	UBERON:0000178	83.83	gold quality
prostate gland	UBERON:0002367	83.63	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	83.22	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.46

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• PVT1 may be a candidate gene which contribute to end stage renal disease susceptibility in diabetes. (PMID:17395743)
• Data indicate that PVT-1 expression is restricted to a low number of normal tissues compared to c-Myc mRNA, whereas the gene is highly expressed in many transformed cell types including neuroblastoma cells that do not express c-Myc. (PMID:17503467)
• Role for PVT1 in mediating susceptibility to end-stage renal disease attributable to diabetes. (PMID:17881614)
• MYC and PVT1 contribute independently to ovarian and breast pathogenesis when overexpressed because of genomic abnormalities (PMID:17908964)
• these results identified PVT1 as a regulator of Gemcitabine sensitivity in pancreatic cancer cells. (PMID:21316338)
• that PVT1 may mediate the development and progression of diabetic nephropathy through mechanisms involving extracellular matrix accumulation. (PMID:21526116)
• we identified a new functional prostate cancer risk variant at the 8q24 locus that is associated with increased expression of PVT1 located 0.5 Mb downstream. (PMID:21814516)
• p53-Dependent induction of PVT1 and miR-1204. (PMID:22110125)
• Data indicate that the PVT1-NBEA and the PVT1-WWOX chimeric genes were associated with the expression of abnormal NBEA and WWOX. (PMID:22869583)
• Deletion or methylation of CDKN2A/2B and PVT1 rearrangement occur frequently in highly aggressive B-cell lymphomas harboring 8q24 abnormality. (PMID:23547836)
• PVT-1, which maps to 8q24, generates antiapoptotic activity in CRC, and abnormal expression of PVT-1 was a prognostic indicator for CRC patients. (PMID:24196785)
• miR-1207-5p, a PVT1-derived microRNA, is abundantly expressed in kidney cells, and is upregulated by glucose and TGF-beta1. (PMID:24204837)
• the GG genotype of SNP rs13281615 plays a role in breast cancer likely by influencing PVT1 expression, and that during oncogenesis, “protective” mutations could occur. (PMID:24780616)
• Report frequency of PVT1 SNPs in diabetic nephropathy. (PMID:24821155)
• Our in vitro findings suggest that C-MYC and PVT1 copy number gains may promote a malignant malignant pleural mesothelioma phenotype. (PMID:24926545)
• Gain of PVT1 long non-coding RNA expression was required for high MYC protein levels in 8q24-amplified human cancer cells (PMID:25043044)
• Oncofetal long noncoding RNA PVT1 promotes proliferation and stem cell-like property of hepatocellular carcinoma cells by stabilizing NOP2. (PMID:25043274)
• our study identified novel PVT1-NSMCE2 and CCDC26-NSMCE2 fusion genes that may play functional roles in leukemia. (PMID:25245984)
• lncRNA PVT1 is significantly upregulated in non-small cell lung cancer. (PMID:25400777)
• PVT1 has a role in competing endogenous RNA activity and regulation of protein stability of important oncogenes, primarily of the MYC oncogene [review] (PMID:25883951)
• LncRNA PVT1 may serve as a candidate prognostic biomarker. (PMID:25890171)
• PVT-1 was highly expressed in gastric cancer tissues of cisplatin-resistant patients and cisplatin-resistant cells. (PMID:25956062)
• we have identified a potential mechanism by which PVT1 regulated by carboplatin plus docetaxel contributes to the carboplatin-docetaxel-induced anticancer action in ovarian cancer. (PMID:26097562)
• lncRNA PVT1 may contribute to tumorigenesis of thyroid cancer through recruiting EZH2 and regulating TSHR expression. (PMID:26427660)
• PVT1 knockdown increased the number of lung cancer cells in the G0/G1 phase and reduced the number of cells in the S phase, while overexpression of PVT1 could promote cell cycle progression. (PMID:26490983)
• Data show that long non-coding RNA PVT1 was upregulated in bladder cancer tissues and cell lines. (PMID:26517688)
• Findings sugggest that the long non-coding RNA (lncRNA) PVT1 may play an important role in the proliferation of acute promyelocytic leukemia (APL) cells and may be useful for future therapeutic management. (PMID:26545364)
• Studies on the association between PVT1 and cancer have shown that PVT1 is a potential oncogene in a variety of cancer types. [review] (PMID:26850852)
• we found that PVT1 functioned as an oncogene and may be a crucial prognostic factor for NSCLC patients. PVT1 contributed to lung adenocarcinoma cell proliferation, partly though EZH2-medicated suppression of the LATS2/MDM2/P53 pathway. (PMID:26908628)
• PVT1 expression was remarkably increased in gastric cancer tissues and cell lines compared with that in the normal control, and its up-regulation was significantly correlated to invasion depth, advanced TNM stage and regional lymph nodes metastasis in gastric cancer. (PMID:26925791)
• our findings indicate that salivary HOTAIR and PVT1 show potential as novel non-invasive biomarkers for detecting pancreatic cancer (PMID:27028998)
• PVT1 expression is significantly increased in ICC tissue versus normal cervix and that higher expression of PVT1 correlates with poorer overall survival (PMID:27232880)
• PVT1 binds to EZH2, recruits EZH2 to the miR-200b promoter, increases histone H3K27 trimethylation level on the miR-200b promoter, and inhibits miR-200b expression. (PMID:27272214)
• Study discloses the role of PVT1 as a novel prognostic factor and as a molecular target for novel therapeutic interventions in renal carcinoma. (PMID:27366943)
• PVT1 regulates both IL-6 release and proliferation in airway smooth muscle cells from patients with severe asthma. (PMID:27484035)
• PVT1 epigenetically down-regulates PTCH1 expression via competitively binding miR-152, contributing to EMT process in liver fibrosis (PMID:27588491)
• Our study suggests that PVT1 promotes tumor progression by interacting with FOXM1 (PMID:27756785)
• Our study suggested a regulatory relationship between lncRNA PVT1 and miR-146a during the process of the prostate cancer tumorigenesis. PVT1 regulated prostate cancer cell viability and apoptosis depending on miR-146a. (PMID:27794184)
• lncRNA PVT1 is overexpressed in osteosarcoma and decreased the survival rate of osteosarcoma patients. Silencing PVT1 by siRNA inhibited proliferation, migration and invasion and promoted apoptosis and cell cycle arrest in osteosarcoma cells via miR-195. (PMID:27813492)
• Identification of CircPVT1, generated by circularization of an exon of the PVT1 gene, as a circular RNA with a function in cell senescence. (PMID:27928058)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.